Researchers reviewed data on patients with chronic hepatitis B who stopped taking nucleos(t)ide analogue (NA) medications. The study looked at the immune system's response to see what factors might predict a successful transition off of these drugs, such as losing the HBsAg marker or maintaining viral control.
The review found that certain signs, like memory B-cell activity and T-cell function, were linked to better outcomes after stopping treatment. In contrast, high levels of inhibitory receptors and inflammatory signals were associated with liver flares and more unstable enzyme levels. These markers are currently considered candidate correlates rather than proven predictors.
Because the data comes from small groups and uses non-standardized tests, these findings are still exploratory. Doctors should not use these immune markers alone to decide when a patient can stop medication. Instead, they should be used alongside viral markers and liver health checks to ensure safe monitoring for patients with chronic hepatitis B.
